Ongoing initiatives against antibiotic shortages – National, regional and global mechanisms to improve access to antibiotics – by Enrico Baraldi and Thomas Tängdén
REVIVE | Advancing Antimicrobial R&D
by Karin Waldhauser
1w ago
PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP is not responsible for the content of external sites. As illustrate ..read more
Visit website
The value of surveillance data in defining the medical need for new antimicrobials
REVIVE | Advancing Antimicrobial R&D
by Victor Kouassi
2w ago
Speakers: Ian Morrissey, Consultant, Antimicrobial Focus Ltd. (UK) Rebecca Li, Executive Director, Vivli (USA) Patricia Bradford, Consultant, Antimicrobial Development Specialists LLC (USA) Moderator: Fernanda Lessa, Chief of International Infection Control, Centers for Disease Control and Prevention (USA) This webinar will show the value of susceptibility surveillance data in defining the need for new antibacterials, designing target product profiles and planning clinical trials. The importance of openly sharing this data will be discussed. It will also feature more information on the 2 ..read more
Visit website
Exploring non-traditional antimicrobials: Insights from three cases
REVIVE | Advancing Antimicrobial R&D
by Victor Kouassi
1M ago
Speakers: Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics (UK) Rida Mourtada, Chief Executive Officer, Lytic Therapeutics (USA) Gregorio Iraola, Chief Executive Officer, Kinzbio (Uruguay) Moderator: Peter Seiler, Member of the Management Team, INCATE (Switzerland) This webinar will feature presentations on the ongoing development of three non-traditional antimicrobials as potential solutions to combat infections. Presentation 1: Immune therapy for infectious disease (Jennifer Schneider) Role of the host in the success of antimicrobial treatment Opportunities to addres ..read more
Visit website
Targeting bacterial virulence to tackle the antimicrobial resistance crisis – by Ronan R. McCarthy
REVIVE | Advancing Antimicrobial R&D
by Karin Waldhauser
1M ago
PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors.  The current antibiotic development pipeline is broken, with a lack ..read more
Visit website
Progressing an antibacterial drug discovery project – an SME perspective
REVIVE | Advancing Antimicrobial R&D
by Shirine Derakhshani
2M ago
Speakers: Alisa Serio, Executive Director of Microbiology and Nonclinical Development, Paratek Pharmaceuticals (USA) Victoria Savage, Chief Scientific Officer, INFEX Therapeutics Ltd (UK) Moderator: Daniel Ritz, Senior Director – Senior Group Leader Biology Technologies / Lead Discovery, Idorsia Pharmaceuticals Ltd. (Switzerland) This webinar will focus on the particular challenges regarding progressing antibacterial drug discovery projects for small and medium-sized enterprises (SMEs) and their potential solutions. Presentation 1: Progression criteria and go/no go decisions in antibacte ..read more
Visit website
Efflux inhibitors: A strategy to tackle multidrug resistance
REVIVE | Advancing Antimicrobial R&D
by Victor Kouassi
3M ago
Speakers: Helen Zgurskaya, Professor, University of Oklahoma (USA) Ruben Hartkoorn, Director of Research, Institut Pasteur de Lille (France) Timothy Opperman, Senior Research Scientist, Microbiotix (USA) Moderator: Laura Piddock, Scientific Director, GARDP (Switzerland) Presentation 1: Deciphering antibiotic resistance: Efflux pumps in bacteria (Helen Zgurskaya) Presentation 2: Discovery of efflux pump inhibitors effective against multi-drug resistant Gram-negative bacteria (Ruben Hartkoorn) Presentation 3: Overcoming the pitfalls of the past to discover clinically useful efflux inhibito ..read more
Visit website
Milestone-driven R&D – Opportunities and challenges
REVIVE | Advancing Antimicrobial R&D
by Victor Kouassi
3M ago
Pre-conference workshop: ‘Milestone-driven R&D – opportunities and challenges’  8th AMR Conference, 5-7 March 2024, Basel, Switzerland Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Speakers: Malcolm Page, Formerly F. Hoffmann-La Roche, Switzerland   Kenneth Bradley, F. Hoffmann-La Roche, Switzerland   Jointly organized by ..read more
Visit website
Progressing a discovery project – Criteria and challenges
REVIVE | Advancing Antimicrobial R&D
by Shirine Derakhshani
3M ago
Speakers: Kenneth Bradley, Global Head, Infectious Disease Discovery, Roche (Switzerland) Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden) Moderator: Karen Bush, Professor of Practice in Biotechnology, Emerita, Indiana University (USA) Presentation 1: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an industry view (Ken Bradley) Drug discovery starts and ends with the patient. Target product profiles (TPPs) guide R&D. Target candidate profiles (TCPs) provide guidance and enable Go/NoGo decision making for preclini ..read more
Visit website
Who will protect (steward) the sheep (antibiotics) from the wolves (antibiotic resistance) and harm’s way (inappropriate use)? – by Debra A. Goff
REVIVE | Advancing Antimicrobial R&D
by Alexandra Santu
4M ago
PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP was not involved in the development of this drug and is not resp ..read more
Visit website
Antimicrobial Chemotherapy Conference 2024
REVIVE | Advancing Antimicrobial R&D
by Victor Kouassi
4M ago
Day 1 Session 1 Session 2 Session 3 Session 4 Session 1 Session 2 Session 3 Session 4 Introductory remarks Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer Session 1 – Keynote presentation Chair: Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer The Quirks of EUCAST: what to consider when hoping for breakpoints for a new agent – from EUCAST and others Professor Gunnar Kahlmeter, Professor of Clinical bacteriology & Head of the EUCAST Development Laboratory Session 2 – Drug discovery: new targets and new chemistry Chair ..read more
Visit website

Follow REVIVE | Advancing Antimicrobial R&D on FeedSpot

Continue with Google
Continue with Apple
OR